A Phase 1 interventional study of BI 730357 and CRESTOR® in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-06.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this trial is to investigate the effect of BI 730357 under steady state conditions on the pharmacokinetics of digoxin, furosemide, metformin and rosuvastatin given as a cocktail (Reference, R: cocktail alone; Test T: cocktail given under steady state conditions of BI 730357).
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male subjects, or female subjects who meet any of the following criteria from at least 30 days before the first administration of trial medication until 30 days after trial completion: -- Use of adequate , e.g. any of the following methods plus condom: implants, injectables, combined oral or vaginal contraceptives, intrauterine device
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cocktail treatment will be followed by the Test treatment in a fixed sequence. The treatment periods are separated by a wash-out phase of at least 14 days between the two cocktail administrations.
Drug: BI 730357 · Drug: CRESTOR® · Drug: Lenoxin® · Drug: MetfoLiquid GeriaSan® · Drug: Lasix®
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Metformin)
Area under the concentration-time curve of Metformin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Metformin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Rosuvastatin)
Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Rosuvastatin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Furosemide)
Area under the concentration-time curve of Furosemide in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Furosemide in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Digoxin)
Area under the concentration-time curve of Digoxin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Digoxin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Maximum Measured Concentration of Metformin in Plasma (Cmax, Metformin)
Maximum measured concentration of Metformin in plasma is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Metformin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax, Rosuvastatin)
Maximum measured concentration of Rosuvastatin in plasma is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Rosuvastatin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Maximum Measured Concentration of Furosemide in Plasma (Cmax, Furosemide)
Maximum measured concentration of Furosemide in plasma is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Furosemide in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Maximum Measured Concentration of Digoxin in Plasma (Cmax, Digoxin)
Maximum measured concentration of Digoxin in plasma is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Digoxin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Metformin)
Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Metformin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Rosuvastatin)
Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Rosuvastatin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Furosemide)
Area under the concentration-time curve of Furosemide in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Furosemide in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Digoxin)
Area under the concentration-time curve of Digoxin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.
Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Digoxin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
This open-label, non-randomised, 2-period fixed-sequence trial in healthy subjects was to test whether BI 730357 affects how 4 other medicines (rosuvastatin, digoxin, metformin, and furosemide) are taken up in the body.
| Milestone | Cocktail (R) / BI 730357+Cocktail (T) |
|---|---|
| Started | 15 |
| Completed | 15 |
| Not completed | 0 |
| Milestone | Cocktail (R) / BI 730357+Cocktail (T) |
|---|---|
| Started | 15 |
| Treated at least one dose of bi | 15 |
| Treated at least one dose of cocktail+bi | 14 |
| Completed | 14 |
| Not completed | 1 |
| Withdrew: Covid-19 related | 1 |
Area under the concentration-time curve of Metformin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.
| hour * nanomole / liter (h*nmol/L) | Metformin (Period 1) | Metformin + BI 730357 (Period 2) |
|---|---|---|
| Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Metformin) | 1460.83 ± NA | 1434.81 ± NA |
Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.
| hour * nanomole / liter (h*nmol/L) | Rosuvastatin (Period 1) | Rosuvastatin + BI 730357 (Period 2) |
|---|---|---|
| Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Rosuvastatin) | 90.08 ± NA | 110.87 ± NA |
Area under the concentration-time curve of Furosemide in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.
| hour * nanomole / liter (h*nmol/L) | Furosemide (Period 1) | Furosemide + BI 730357 (Period 2) |
|---|---|---|
| Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Furosemide) | 157.57 ± NA | 185.50 ± NA |
Area under the concentration-time curve of Digoxin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.
| hour * nanomole / liter (h*nmol/L) | Digoxin (Period 1) | Digoxin + BI 730357 (Period 2) |
|---|---|---|
| Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Digoxin) | 13.34 ± NA | 22.71 ± NA |
Maximum measured concentration of Metformin in plasma is reported. The geometric mean is actually adjusted geometric mean.
| nanomole / liter (nmol/L) | Metformin (Period 1) | Metformin + BI 730357 (Period 2) |
|---|---|---|
| Maximum Measured Concentration of Metformin in Plasma (Cmax, Metformin) | 235.86 ± NA | 215.63 ± NA |
Maximum measured concentration of Rosuvastatin in plasma is reported. The geometric mean is actually adjusted geometric mean.
| nanomole / liter (nmol/L) | Rosuvastatin (Period 1) | Rosuvastatin + BI 730357 (Period 2) |
|---|---|---|
| Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax, Rosuvastatin) | 6.92 ± NA | 9.63 ± NA |
Maximum measured concentration of Furosemide in plasma is reported. The geometric mean is actually adjusted geometric mean.
| hour * nanomole / liter (h*nmol/L) | Furosemide (Period 1) | Furosemide + BI 730357 (Period 2) |
|---|---|---|
| Maximum Measured Concentration of Furosemide in Plasma (Cmax, Furosemide) | 51.03 ± NA | 57.21 ± NA |
Maximum measured concentration of Digoxin in plasma is reported. The geometric mean is actually adjusted geometric mean.
| nanomole / liter (nmol/L) | Digoxin (Period 1) | Digoxin + BI 730357 (Period 2) |
|---|---|---|
| Maximum Measured Concentration of Digoxin in Plasma (Cmax, Digoxin) | 0.87 ± NA | 1.40 ± NA |
Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.
| hour * nanomole / liter (h*nmol/L) | Metformin (Period 1) | Metformin + BI 730357 (Period 2) |
|---|---|---|
| Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Metformin) | 1450.30 ± NA | 1424.70 ± NA |
Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.
| hour * nanomole / liter (h * nmol/L) | Rosuvastatin (Period 1) | Rosuvastatin + BI 730357 (Period 2) |
|---|---|---|
| Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Rosuvastatin) | 78.83 ± NA | 93.54 ± NA |
Area under the concentration-time curve of Furosemide in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.
| hour * nanomole / liter (h*nmol/L) | Furosemide (Period 1) | Furosemide + BI 730357 (Period 2) |
|---|---|---|
| Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Furosemide) | 151.01 ± NA | 172.26 ± NA |
Area under the concentration-time curve of Digoxin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.
| hour * nanomole / liter (h*nmol/L) | Digoxin (Period 1) | Digoxin + BI 730357 (Period 2) |
|---|---|---|
| Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Digoxin) | 11.00 ± NA | 19.11 ± NA |
Collected over Cocktail: From 1st dose of cocktail until 1st dose of BI 730357 (BI) or end of 10 days residual effect period (REP) of cocktail, whichever occurs earlier, up to 10 days. Cocktail+BI: the period where the REP of the 1st dose of cocktail overlaps with the start of the dosing of BI, up to 3 days. BI: From 1st dose of BI or end of 10 days REP (whichever occurs later) until 2nd dose of cocktail, up to 7 days. BI+Cocktail: From 2nd dose of cocktail until last dose of BI+7 days of REP, up to 13 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cocktail (Period 1) | 0/15 (0%) | 0/15 (0%) | 6/15 (40%) |
| Cocktail+BI 730357 (Overlap Period) | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| BI 730357 (Period 2) | 0/15 (0%) | 0/15 (0%) | 4/15 (26.7%) |
| BI 730357+Cocktail (Period 2) | 0/14 (0%) | 0/14 (0%) | 4/14 (28.6%) |
| Event | Cocktail (Period 1) | Cocktail+BI 730357 (Overlap Period) | BI 730357 (Period 2) | BI 730357+Cocktail (Period 2) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 5/15 | 0/15 | 0/15 | 2/14 |
| ParosmiaNervous system disorders | 0/15 | 0/15 | 0/15 | 1/14 |
| MalaiseGeneral disorders | 0/15 | 0/15 | 0/15 | 1/14 |
| NasopharyngitisInfections and infestations | 0/15 | 0/15 | 0/15 | 1/14 |
| Dry skinSkin and subcutaneous tissue disorders | 0/15 | 0/15 | 0/15 | 1/14 |
| DizzinessNervous system disorders | 1/15 | 0/15 | 0/15 | 0/14 |
| Back painMusculoskeletal and connective tissue disorders | 0/15 | 0/15 | 1/15 | 0/14 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/15 | 0/15 | 1/15 | 0/14 |
| FatigueGeneral disorders | 1/15 | 0/15 | 1/15 | 0/14 |
| Skin erosionSkin and subcutaneous tissue disorders | 1/15 | 0/15 | 0/15 | 0/14 |
Treated set (TS): The treated set includes all subjects who signed informed consent and were treated with at least one dose of study drug.
| Age, Continuous(Years) | Cocktail (R) / BI 730357+Cocktail (T) |
|---|---|
| Mean | 34.2 ± 7.6 |
| Sex: Female, Male(Participants) | Cocktail (R) / BI 730357+Cocktail (T) |
|---|---|
| Female | 5 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | Cocktail (R) / BI 730357+Cocktail (T) |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Cocktail (R) / BI 730357+Cocktail (T) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).For more details refer to: http://trials.boehringer-ingelheim.com/
Ran from Oct 2020 to primary completion in Jan 2021, 2 months.
Results were first posted in Jul 2023, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevurogant · Rosuvastatin · Digoxin · Metformin · Furosemide